violetsunset-shutterstock-com
Violetsunset / Shutterstock.com
8 June 2015Americas

Federal Circuit hears arguments in Zarxio ‘patent dance’ row

The US Court of Appeals for the Federal Circuit has heard oral arguments in Amgen v Sandoz, a case that should determine whether it is mandatory for biosimilar applicants to engage in the so-called patent dance.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.

More on this story

Americas
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.

More on this story

Americas
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.